ArticleBioinformatics (Oxford, England)2026
aiSysMet: AI-powered systems metabolomics for biomarker discovery.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
motivationMetabolomics plays an essential role in the growing systems biology approaches to unravel the relationships between metabolites and diseases. Liquid chromatography-mass spectrometry (LC-MS) is central to this effort because it can profile many metabolites from limited material. Yet, in a typical untargeted LC-MS-based metabolomics study, the majority of detected peaks remain unannotated, largely due to incomplete spectral libraries and uncertainties in peak picking, alignment, and the handling of isotopes and adducts. These limitations hinder seamless integration with other omics layers.
resultsWe developed an AI-powered platform (aiSysMet) that uses statistical, machine learning, and deep learning methods for metabolomics data processing, metabolite annotation, and integrative analysis of multi-omics data. The platform's interactive and modular web interface allows users to easily build data analysis pipelines that can be executed in the cloud. AVAILABILITY: aiSysMet is freely available for non-commercial users on https://tools.omicscraft.com/aiSysMet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.